Compare Rockwell Automation (ROK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Vertex Pharmaceuticals Incorporated — how do they compare? Rockwell Automation trades at $426.07 (market cap $47.65B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× Rockwell Automation's market cap, and Rockwell Automation pays a 1.29% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ROK | VRTX | |
|---|---|---|
Market Cap | $47.65B | $134.06B |
Sector | Industrials | Health |
52-Week High | $495.08 | $557.96 |
52-Week Low | $333.75 | $376.62 |
Enterprise Value | $50.79B | $128.18B |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and near-term support at $427. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34B, with a net income margin of 13.38%, though profitability has moderated from 2023 peaks. Recent news highlights expansion in AI-driven quality systems and remote support capabilities.
The stock offers a 19.8% upside to the consensus price target of $514, supported by analyst optimism on margin expansion and reshoring trends. However, high valuation multiples (P/E 40.18) and mixed technical indicators suggest near-term volatility. Key risks include execution on growth initiatives and macroeconomic pressures on industrial spending.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
